

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of )  
Lee, et al. ) Art Unit: 1612  
Application No. 10/502,495 ) Examiner: Maewall, S  
Filed: June 24, 2005 ) Confirmation No. 5458  
FOR: DERMAL APPLICATION SYSTEM )  
FOR AMINOLEVULINIC )  
ACID-DERIVATIVES )

## **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

MAIL STOP A/F  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

BALLARD SPAHR ANDREWS &  
INGERSOLL, LLP  
Customer Number 23859

May 4, 2009

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. § 1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

The Applicants now submit copies of Office Actions, Amendments, Responses, and other correspondence from the prosecution of the applications listed below. A list of the correspondence is provided in Appendix A. Pursuant to 37 C.F.R. § 1.98(a)(2)(iv), the Applicants have enclosed copies of correspondence.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(d), in that it is being filed on or before the payment of the issue fee, and either a final Office Action or a Notice of Allowance has been mailed to Applicants. Accordingly, Applicants enclose the fee required under 37 C.F.R. § 1.97(d)(2) and make the statement required under 37 C.F.R. § 1.97(e)(2).

The undersigned hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

ATTORNEY DOCKET NO. 21127.0008U1  
APPLICATION NO. 10/502,495

A credit card payment submitted *via* EFS Web in the amount of \$180.00, representing the fee under 37 C.F.R. § 1.17(p), is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

BALLARD SPAHR ANDREWS &  
INGERSOLL, LLP

  
\_\_\_\_\_  
P. Brian Giles, Ph.D.  
Registration No. 57,896

Customer Number 23859  
(678) 420-9300 Phone  
(678) 420-9301 Fax

CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. § 1.8			
I hereby certify that this correspondence, including any items indicated as attached or included, is being transmitted via electronic transmission via EFS-Web on the date indicated below.			
Name of Person Mailing (Print/Type)	P. Brian Giles, Ph.D.		
Signature		Date	5-4-2009